Glucophage (Metformin Hydrochloride)

Glucophage is indicated primarily for the treatment of type 2 diabetes mellitus in adults, and may be used as part of a comprehensive management plan that includes diet and exercise.

• As monotherapy for patients whose blood glucose is not adequately controlled by diet and exercise.
• In combination with other oral antidiabetic agents such as sulfonylureas or DPP‑4 inhibitors.
• As an adjunct to insulin therapy to reduce required insulin dose.
• For patients with overweight or obesity to aid glycemic control while limiting weight gain.
• In some cases, for pre‑diabetes management under specialist guidance.

Glucophage may cause a range of adverse effects; most are mild, dose‑related, and transient, while a few are rare but potentially serious and require prompt medical attention.

Common

• Nausea, vomiting, or abdominal discomfort, especially when therapy is initiated or the dose is increased.
• Diarrhea or loose stools that usually improve with continued use.
• Metallic taste in the mouth after taking the tablet.
• Decreased appetite or mild weight loss, often observed during the first weeks of therapy.

Serious

• Lactic acidosis presenting with rapid breathing, muscle pain, abdominal discomfort, or unusual fatigue; this condition is rare but life‑threatening.
• Severe hypoglycemia when Glucophage is combined with insulin or insulin‑secretagogue agents, characterized by sweating, confusion, or loss of consciousness.
• Skin reactions such as rash, erythema, or Stevens‑Johnson syndrome, which require immediate discontinuation.
• Persistent gastrointestinal distress not improving after several weeks, requiring evaluation.

When prescribing Glucophage, clinicians consider several precautions to ensure safe use and to minimize the risk of complications.

• Assess renal function before initiation and periodically thereafter; contraindicated in severe renal impairment.
• Evaluate hepatic function, as liver disease may increase the risk of lactic acidosis.
• Use caution in patients with heart failure or a history of cardiovascular disease.
• Monitor vitamin B12 levels during long‑term therapy, as metformin can reduce absorption.
• Adjust dose or discontinue during radiologic procedures using iodinated contrast agents.
• Avoid use during pregnancy unless benefits outweigh risks; safety data are limited.

Glucophage can interact with other medicines, affecting its efficacy or increasing the risk of adverse events; some combinations should be avoided, while others require careful monitoring.

Avoid

• Concomitant use with iodinated contrast agents without adequate hydration and renal monitoring.
• Co‑administration with potent CYP450 inhibitors that may alter metformin clearance (though metformin is not significantly metabolized, caution is advised).
• Use with other antidiabetic agents that cause hypoglycemia without dose adjustment.

Use with caution

• Combination with sulfonylureas or insulin may increase hypoglycemia risk; dose adjustments may be needed.
• Concurrent use of cimetidine or other renal tubular secretion inhibitors can raise metformin plasma levels.
• NSAIDs or diuretics that affect renal function may require closer monitoring of kidney parameters.